N-Gene Research Laboratories, Inc. is a pharmaceutical company with a pipeline of proprietary drugs to treat insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging. BGP-15, N-Gene's lead compound is a coinducer of HSP-72 that increases insulin sensitivity via blocking JNK phosphorylation (Febbraio et al., PNAS (2008) 105, 1739–1744).